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Abstract
Background: Osteoarthritis (OA) is a chronic debilitating joint disorder of particularly high prevalence in the elderly
population. Intra-articular basic calcium phosphate (BCP) crystals are present in the majority of OA joints and are
associated with severe degeneration. They are known to activate macrophages, synovial fibroblasts, and articular
chondrocytes, resulting in increased cell proliferation and the production of pro-inflammatory cytokines and matrix
metalloproteases (MMPs). This suggests a pathogenic role in OA by causing extracellular matrix degradation and
subchondral bone remodelling. There are currently no disease-modifying drugs available for crystal-associated OA;
hence, the aim of this study was to explore the inflammatory pathways activated by BCP crystals in order to
identify potential therapeutic targets to limit crystal-induced inflammation.
Methods: Primary human macrophages and dendritic cells were stimulated with BCP crystals, and activation of
spleen tyrosine kinase (Syk), phosphoinositide-3 kinase (PI3K), and mitogen-activated protein kinases (MAPKs) was
detected by immunoblotting. Lipopolysaccharide (LPS)-primed macrophages were pre-treated with inhibitors of
Syk, PI3K, and MAPKs prior to BCP stimulation, and cytokine production was quantified by enzyme-linked
immunosorbent assay (ELISA). Aa an alternative, cells were treated with synovial fluid derived from osteoarthritic
knees in the presence or absence of BCP crystals, and gene induction was assessed by real-time polymerase
chain reaction (PCR).
Results: We demonstrate that exposure of primary human macrophages and dendritic cells to BCP crystals leads
to activation of the membrane-proximal tyrosine kinases Syk and PI3K. Furthermore, we show that production of
the pro-inflammatory cytokines interleukin (IL)-1α and IL-1β and phosphorylation of downstream MEK and ERK
MAPKs is suppressed following treatment with inhibitors of Syk or PI3K. Finally, we demonstrate that treatment of
macrophages with BCP crystals induces the production of the damage-associated molecule S100A8 and MMP1 in
a Syk-dependent manner and that synovial fluid from OA patients together with BCP crystals exacerbates these effects.
Conclusions: We identify Syk and PI3K as key signalling molecules activated by BCP crystals prior to inflammatory
cytokine and DAMP expression and therefore propose that Syk and PI3K represent potential targets for the treatment
of BCP-related pathologies.
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Background
It is well established that intra-articular deposition of
particulates, such as gout-associated monosodium urate
(MSU) crystals and osteoarthritis (OA)-associated basic
calcium phosphate (BCP) crystals, drives joint degener-
ation through the production of pro-inflammatory cyto-
kines and cartilage-degrading proteases. BCP crystals are
a heterogeneous group of ultramicroscopic crystalline
substances composed mainly of hydroxyapatite (HA),
along with smaller proportions of its precursor forms
octacalcium phosphate (OCP) and tricalcium phosphate
[1, 2]. The concentration of BCP crystals found in the
synovial fluid is reported to be between 20 and 100 μg/ml
[3–5]. Furthermore, a 3-year prospective analysis of
synovial fluid (SF) samples obtained from 330 patients
with knee OA showed that the initial presence of BCP
crystals was associated with worsening of radiographic
lesions [6]. The concentration in the tissues is more dif-
ficult to quantify; however, Fuerst and colleagues dem-
onstrated that human knee and hip cartilage specimens
(n = 120 and n = 80, respectively), harvested at the time
of total joint arthroplasty for primary OA, contained
BCP crystals in 100% of cases [7, 8]. Sun et al. have also
reported calcium deposition in all eight OA menisci
harvested at the time of joint replacement surgery and
that calcium crystal formation could be generated by
both the meniscal and cartilage cells of patients with
end-stage OA [9]. As crystal deposition does not occur
in healthy cartilage, it is becoming more widely ac-
cepted that cartilage calcification plays a pathogenic
role in OA and that BCP crystals are not the “innocent
bystanders” that they were once believed to be. Indeed,
the crystals are now considered to be a damage-
associated molecular pattern (DAMP) as they can acti-
vate fibroblasts through a variety of signalling pathways
involving protein kinase C (PKC), ERK1/2 mitogen-
activated protein kinases (MAPKs), and transcription
factors such as NFκB which, in turn, leads to the pro-
duction of tumour necrosis factor (TNF)α, interleukin
(IL)-6, and IL-1β [10, 11]. Cytokine induction has also
been observed in BCP-activated chondrocytes [12] and
macrophages [13–16], with IL-1β, in particular, impli-
cated as a key player in the inflammatory and degrada-
tive responses observed in OA joints. It is induced early
on in the disease and has the ability to upregulate
matrix metalloproteases (MMPs) and aggrecanases, in-
duce cell infiltration into the joints, promote osteoclas-
togenesis, and suppress the biosynthesis of type II
collagen and aggrecan, crucial components of cartilage
[17–20]. We have recently demonstrated that BCP crys-
tals can inhibit anti-osteoclastogenic cytokine signal-
ling, and therefore the crystals may also contribute to
joint destruction by promoting the differentiation of
bone-resorbing osteoclasts [21]. Together, these events
lead to an imbalance in the production of anabolic ver-
sus catabolic mediators and, in many cases, total joint
replacement is eventually required.
Current therapies for OA focus merely on pain relief
and improvement of joint function rather than halting
disease progression. While much progress has been
made in elucidating the cellular and molecular events
contributing to OA, the complex nature of the disease
has hampered the development of a successful disease-
modifying drug despite a multitude of potential targets.
We and others have previously reported that BCP crys-
tals activate the NLRP3 inflammasome in vitro leading
to potent IL-1β production. However, conflicting results
from in vivo models have called into question the rele-
vance of these findings to a clinical setting, and add-
itional targets are currently being sought [14, 16, 22].
Another potential target of interest in particulate-
mediated disease is the membrane-proximal kinase,
spleen tyrosine kinase (Syk). Belonging to the tyrosine
kinase family, Syk is activated during phagocytosis and
following Fc receptor engagement on immune cells [23].
Syk has been implicated in both the internalisation of
MSU crystals and subsequent MSU-induced signalling
in neutrophils and dendritic cells (DC) [24, 25]. In
addition to MSU crystals, alum particles and cholesterol
crystals have also been reported to activate Syk in a
receptor-independent manner, by a process known as
membrane affinity-triggered signalling (MATS). This
involves direct binding of the particulates to the cell
membrane which results in lipid raft formation and ag-
gregation of immunoreceptor tyrosine-based activation
motif (ITAM)-containing molecules which mediate the
recruitment of Syk to the plasma membrane and its
subsequent activation [26, 27]. We have previously dem-
onstrated that BCP crystals activate Syk and its down-
stream interacting partner, phosphoinositide-3 kinase
(PI3K), in murine macrophages [16]. Therefore, the aim
of this study was to determine whether BCP crystals ac-
tivate similar pathways in human macrophages and DC
and to examine the downstream effect of inhibiting
these pathways in order to identify potential therapeutic
targets to treat crystal-induced inflammation in OA.
Methods
Reagents
Ultrapure lipopolysaccharide (LPS) and the PI3K inhibi-
tor, LY294002, were from Invivogen (Toulouse, France).
The Syk inhibitor, R788, was from AdooQ BioScience
(Irvine, CA, USA). Recombinant human M-CSF was
from PeproTech (Rocky Hill, NJ, USA). Recombinant
human IL-4 and GM-CSF were from Immunotools
(Friesoythe, Germany). Lymphoprep was from Stemcell
Technologies (Grenoble, France). Primary antibodies
were obtained from Cell Signaling Technology (Beverly,
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MA, USA). The Syk inhibitor, piceatannol, methyl-β-
cyclodextrin (M-βCD), secondary antibodies, cell culture
reagents and all other chemicals were from Sigma Al-
drich (St. Louis, MO, USA). Human FcR binding inhibi-
tor was from eBioscience. BCP crystals were synthesized
by alkaline hydrolysis of brushite as described previously
[28] and contain partially carbonate-substituted hydroxy-
apatite in addition to octacalcium phosphate. OA synovial
fluid was obtained with permission from The Mater Mis-
ericordiae Hospital Research Ethics Committee.
Cell culture and differentiation
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by means of density gradient centrifugation from
leukocyte-enriched buffy coats from anonymous healthy
donors, obtained with permission from the Irish Blood
Transfusion Board, St. James’s Hospital, Dublin. CD14+
cells were positively selected using anti-CD14 magnetic
beads (Miltenyi Biotech, Germany) and shown to be
>90% pure, as determined by flow cytometry. Cells were
cultured for 6 days in six-well plates (for immunoblot-
ting assays) or 24-well plates (for real-time polymerase
chain reaction (PCR) and enzyme-linked immunosorb-
ent assay (ELISA)) in RPMI 1640 medium supplemented
with 1% penicillin-streptomycin and 10% foetal bovine
serum. Cells were treated on days 0 and 3 with M-CSF
(50 ng/ml) for macrophage differentiation or IL-4
(40 ng/ml) and GM-CSF (50 ng/ml) for DC differenti-
ation (as adapted from [29, 30]). Cells were shown to be
>95% pure as determined by flow cytometry, using
CD14 and CD11b as macrophage markers and CD14
and CD209 as DC markers [31, 32].
Kinase activation
Primary macrophages or DC (2 × 106/well) were stimu-
lated with BCP crystals (50 μg/ml) over the course of
30 min. Alternatively, cells were pre-treated with picea-
tannol, R788, or LY294002 for 30 min prior to crystal
stimulation. Cells were lysed by the addition of RIPA
buffer (Tris 50 mM; NaCl 150 mM; SDS 0.1%; sodium
deoxycholate 0.5%; Triton X 100) containing phosphat-
ase inhibitor cocktail 3 (Sigma-Aldrich). Samples were
electrophoresed on a 12% SDS-polyacrylamide gel and




Primary macrophages (5 × 105/well) were primed with a
known TLR4 activator, LPS (100 ng/ml), for 2 h prior to
treatment with piceatannol, LY294002, M-βCD, or a hu-
man FcR binding inhibitor for 1 h and stimulation with
BCP crystals (50 μg/ml) for 6 h. Supernatants were har-
vested and cytokine concentrations were quantified by
ELISA (R&D Systems). S100A8 is also capable of activat-
ing TLR4; therefore, in order to determine whether this
DAMP could be used to facilitate pro-IL-1β induction,
in place of LPS, primary macrophages (5 × 105/well)
were primed with endotoxin-free recombinant S100A8
(1 μg/ml) for 3 h prior to stimulation with BCP crystals
(50 μg/ml) for 6 h, and cytokine concentrations were
quantified by ELISA.
Real-time PCR
Human macrophages (5 × 105/well) were treated with
BCP crystals alone for 3, 6, or 24 h or were pre-treated
with piceatannol (50 μM, 100 μM) or LY294002 (25 μM,
50 μM) prior to BCP crystal treatment for 6 h. Alterna-
tively, human macrophages were treated with OA syn-
ovial fluid alone or in combination with BCP crystals for
24 h. RNA was extracted using High Pure RNA Isolation
Kits (Roche) and assessed for concentration and purity
using the NanoDrop 2000c UV-Vis spectrophotometer.
RNA was equalised and reverse transcribed using the
Applied Biosystems High-Capacity cDNA reverse tran-
scription kit. Real-time PCR was carried out on triplicate
cDNA samples with the use of the CFX96 Touch Real-
Time PCR Detection System (Bio-Rad Laboratories,
CA, USA). Reactions included TaqMan fast universal
PCR Master Mix (Applied Biosystems), cDNA and pre-
designed TaqMan S100A8, and MMP1 and TIMP1
gene expression probes (Applied Biosystems). mRNA
expression data were normalised to the housekeeping
gene, 18S ribosomal RNA, and relative gene expression
levels were analysed using the 2−ΔΔCT method.
Statistical analysis
All experiments were run at least three times. For
real-time PCR and ELISA, three technical replicates,
per donor, were obtained and the mean for each
donor ± SEM was then plotted for n ≥ 3 healthy do-
nors. Statistical analysis was performed by one-way
analysis of variance (ANOVA) with Tukey post-test
where applicable or Student’s t test when comparing
only two observations. All experiments were run at
least three times and analysed on GraphPad Prism 6
software. A P value ≤ 0.05 was deemed statistically
significant.
Results
BCP crystals activate Syk and PI3K in primary human
macrophages and DC
We have previously demonstrated that BCP crystals acti-
vate the membrane-proximal tyrosine kinase Syk in
murine bone marrow-derived macrophages (BMDM)
[16]. It is also reported to be activated by MSU crystals,
alum particles, and cholesterol crystals [24–27]. In order
to determine if BCP crystals can induce the activation of
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Syk in human innate immune cells, primary macro-
phages and DC were stimulated with BCP crystals
(50 μg/ml) over the course of 30 min. This concentra-
tion of BCP crystals was chosen as it is within the range
used in previously published studies [14, 15, 22] and is
considered to be physiologically relevant as the concen-
tration in OA synovial fluid ranges between 20 and
100 μg/ml [3–5]. Activation of Syk, as indicated by
phosphorylation, was examined by immunoblotting.
Phosphorylation of Syk was detected in both macro-
phages (Fig. 1a) and DC (Fig. 1b) within 2 min of BCP
crystal treatment and increased in the first 10 min.
Densitometric analysis of three Western blots revealed
that maximal phosphorylation occurs at 10 min post-
stimulation in both cell types (Fig. 1c and d).
Having demonstrated that BCP crystals are capable of
activating Syk in both primary human macrophages
and DC, we next sought to determine whether PI3K (a
known interacting partner) is activated by BCP crystals
downstream of Syk. Robust phosphorylation of the
regulatory p85 and p55 subunits of the enzyme was de-
tected in both macrophages (Fig. 1e) and DC (Fig. 1f )
within 10 min of crystal treatment, with densitometric
analysis of three Western blots revealing that maximal
phosphorylation occurs at between 10 and 30 min in
both cell types (Fig. 1g and h).
BCP crystals drive IL-1 production by primary
macrophages in a Syk- and PI3K-dependent manner
BCP crystals are known to drive IL-1β production in
murine macrophages that have been primed, for ex-
ample, with a TLR agonist such as LPS [14–16]. Priming
serves to induce pro-IL-1β expression within the cell
while subsequent treatment of cells with the crystals
leads to IL-1β processing and secretion. In an in vitro
setting, this event is mediated by the NLRP3 inflamma-
some and active caspase-1, whereas it is likely to be me-
diated by alternative enzymes such as granzymes in the
diseased joint [15]. In order to investigate if Syk is in-
volved in BCP crystal-induced IL-1 production, primary
human macrophages were primed with LPS (100 ng/
ml) for 2 h prior to treatment with piceatannol, a
pharmacological inhibitor of Syk, for 1 h and stimula-
tion with BCP crystals for 6 h. Treatment with the Syk
inhibitor resulted in a dose-dependent reduction in
BCP crystal-induced IL-1β production, while having no
effect on LPS-induced TNF-α which occurs independ-
ently of caspase-1 activation (Fig. 2a and c). Syk inhib-
ition also significantly reduced IL-1α secretion (Fig. 2b)
which is known to coincide with IL-1β release during
pyroptosis. Similar results were obtained with an add-
itional Syk inhibitor, R788, which is orally available
(data not shown).
Fig. 1 BCP crystals activate Syk and PI3K in primary macrophages and DC. a, e Human macrophages and b, f DC (2 × 106 cells/well) were
stimulated with BCP crystals (50 μg/ml) for the indicated time points, and phosphorylation of Syk and PI3K was detected by immunoblotting
using phospho-specific antibodies. Representative blots of three independent experiments are shown. c, d, g, h Densitometric analysis of three
blots was performed using ImageJ software. Bar graphs illustrate the mean (± SEM) increase in phosphorylation, relative to the untreated sample
(0) and normalised to total Syk/PI3K protein. *P≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001
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In order to determine the effect of PI3K inhibition on
BCP crystal-induced IL-1 production, LPS-primed hu-
man macrophages were pre-treated with the PI3K in-
hibitor, LY294002, for 1 h prior to BCP crystal
stimulation. Similar to Syk inhibition, PI3K inhibition
significantly reduced both IL-1α and IL-1β secretion,
once again having no effect on LPS-induced TNFα pro-
duction (Fig. 2d–f ). This suggests that activation of Syk
and PI3K is directly coupled to BCP crystal-induced
cytokine production.
BCP crystal-induced IL-1 production occurs via lipid raft
formation in primary human macrophages
Syk is typically activated following FcγR engagement
which induces ITAM phosphorylation [23]; however,
recent studies have demonstrated that MSU crystals,
cholesterol crystals, and alum particles are capable of
directly binding to the plasma membrane and activat-
ing Syk in a receptor-independent manner via MATS
[24–27]. In order to ascertain whether MATS or FcγR
activation is involved in BCP crystal-induced IL-1
production, LPS-primed human macrophages were ei-
ther treated with an FcγR neutralising antibody or de-
pleted of membrane cholesterol with M-βCD (10 mM)
to prevent lipid sorting, prior to stimulation with BCP
crystals. Blockade of the FcγR had no effect on BCP
crystal-induced IL-1 production (Fig. 3a and b) whereas
treatment with M-βCD significantly reduced BCP
crystal-induced IL-1β production (Fig. 3d) and, while
not statistically significant, also reduced IL-1α (Fig. 3e).
Neither FcγR blockade nor M-βCD treatment affected
LPS-induced TNFα (Fig. 3c and f ). These results sug-
gest that, like alum particles, MSU, and cholesterol
crystals, BCP crystals may activate cell signalling path-
ways and drive cytokine production by primary macro-
phages through direct interaction with the plasma
membrane.
BCP crystals activate MEK and ERK MAPK in primary
human macrophages and DC
It well known that MEK and ERK MAPK are activated
downstream of Syk and PI3K [33]. In addition, BCP
Fig. 2 Inhibition of Syk and PI3K reduces BCP crystal-induced IL-1 production in primary macrophages. Human macrophages (0.5 × 106 cells/well)
were primed with LPS (100 ng/ml) for 2 h prior to treatment with a–c piceatannol (10 μM, 25 μM, and 50 μM) or d–f LY294002 (10 μM, 25 μM,
and 50 μM) for 1 h and stimulation with BCP crystals (50 μg/ml) for 6 h. Cell supernatants were assessed for IL-1β, IL-1α, and TNF-α by ELISA.
Results indicate mean (± SEM) of three independent experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 vs LPS + BCP
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crystals have been shown to activate MAPKs in human
fibroblasts and osteoclast precursor cells [16, 21, 34]. In
order to determine whether BCP crystals can activate
MAPKs in human innate immune cells, and to deter-
mine if this is associated with the activation of
membrane-proximal kinases, primary macrophages and
DC were stimulated with BCP crystals over the course
of 30 min and MEK/ERK activation, as indicated by
phosphorylation, was assessed by immunoblotting.
Robust BCP crystal-induced phosphorylation of MEK
and ERK was evident after 2 min in macrophages (Fig. 4a
and b; corresponding densitometry is also shown). While
basal phosphorylation of MEK and ERK was higher in
DC than in macrophages, densitometric analysis of three
Western blots from individual donors revealed that
phosphorylation of both kinases was significantly in-
creased following BCP treatment (Fig. 4c and d; corre-
sponding densitometry is also shown).
In order to confirm that BCP crystal-induced MEK/
ERK activation occurs downstream of Syk and PI3K, pri-
mary human macrophages and DC were pre-treated for
30 min with one of two Syk inhibitors, piceatannol
(50 μM or 100 μM) or R788 (5 μM), or the PI3K inhibi-
tor, LY294002 (50 μM), prior to stimulation with BCP
crystals for 15 min. As previously observed, BCP crystals
induced the phosphorylation of MEK and ERK in pri-
mary macrophages (Fig. 4e and f; corresponding densi-
tometry is also shown) and DC (Fig. 4g and h;
corresponding densitometry is also shown) and this was
reduced when either Syk or PI3K were inhibited, which
demonstrates that BCP crystals activate MAPKs in a
Syk- and PI3K-dependent manner.
BCP crystals upregulate the damage-associated molecules,
S100A8, S100A12, and MMP1 in primary macrophages in a
Syk- and PI3K-dependent manner
The calgranulins, specifically S100A8 and S100A9, have
been implicated in both rheumatoid arthritis and OA
and are considered potent damage-associated molecules
which exacerbate inflammation following their release
under conditions of cellular stress or injury [35, 36]. In a
collagenase-induced OA model, S100A8 and S100A9
Fig. 3 BCP crystal-induced IL-1 production occurs via lipid raft formation in primary macrophages. LPS-primed human macrophages were treated
with a–c an Fc receptor blocking antibody (5 μg/ml) or d–f M-βCD (10 mM) for 1 h prior to BCP crystal stimulation for 6 h. Cell supernatants were
assessed for IL-1β, IL-1α, and TNF-α by ELISA. Results indicate mean (± SEM) of three independent experiments. ***P < 0.001
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expression remained elevated long after inflammatory
cytokine levels had subsided, while in a BCP crystal-
induced peritonitis model, both peritoneal and serum
concentrations of S100A8 and S100A9 were increased
[35–37]. Studies from our laboratory have demonstrated
that BCP crystals can directly induce the upregulation of
S100A8 in murine macrophages [16]; therefore, experi-
ments were next carried out in order to determine
whether these crystals also induce the expression of this
DAMP in human immune cells. We also examined ex-
pression of the DAMP, S100A12, which, although not as
widely studied as S100A8, has also been implicated in
OA [38]. Primary human macrophages were stimulated
with BCP crystals for 3, 6, and 24 h, and expression of
S100A8 and S100A12 was analysed by real-time PCR. A
time-dependent increase in S100A8 and S100A12
mRNA was observed in response to BCP crystal treat-
ment, with significant induction observed at 24 h
post-stimulation (Fig. 5a and b). We also examined the
expression of MMP1, MMP2, and MMP9 given their
known association with cartilage destruction in OA
[39, 40]. As with the S100 proteins, MMP1 mRNA was
significantly elevated after 24 h of crystal treatment
(Fig. 5c). There was also a modest increase in MMP2
(Fig. 5d), whereas there was no significant effect on
MMP9 or the MMP inhibitor, TIMP1 (Fig. 5e and f ).
An increase in S100A8 protein expression was also de-
tected in cell lysates after 3 h, suggesting a rapid
mRNA turnover (Fig. 5g), while a time-dependent in-
crease in the secreted and active forms of MMP1 and
S100A12 was detected in the cell supernatants (Fig. 5h
and i), which may further exacerbate damage at a site
of inflammation.
We next examined the effect of Syk, PI3K, and MAPK
inhibition on the induction of S100A8, S100A12, and
MMP1 by BCP crystals. Macrophages were pre-treated
with the Syk inhibitor, piceatannol, the PI3K inhibitor,
LY294002, or the ERK/MEK inhibitor, PD98059, for
30 min prior to BCP crystal treatment for 24 h, and ex-
pression of S100A8, S100A12, MMP1, and TIMP1 was
analysed by real-time PCR. All three inhibitors signifi-
cantly reduced BCP crystal-induced S100A8, S100A12,
and MMP1 expression (Fig. 6a–c) suggesting that all
three signalling molecules are involved in their
Fig. 4 BCP crystals activate MEK and ERK downstream of Syk/PI3K in primary macrophages and DC. a,b Human macrophages and c, d DC
(2 × 106 cells/well) were stimulated with BCP crystals (50 μg/ml) for the indicated time points. Phosphorylation of MEK and ERK was detected
by immunoblotting using phospho-specific antibodies. e,f Human macrophages and g,h DC were pre-treated with piceatannol (50 μM,
100 μM; lanes 3, 4), R788 (5 μM; lane 5), or LY294002 (50 μM; lane 6) for 30 min prior to stimulation with BCP crystals for 15 min. Phosphorylation of
MEK and ERK was detected by immunoblotting. Representative blots of three independent experiments are shown. Densitometric analysis of three
blots was performed using ImageJ software. Bar graphs illustrate the mean (± SEM) increase in phosphorylation, relative to the untreated sample (0)
and normalised to total MEK/ERK protein. *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001
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induction. The ERK inhibitor reduced basal TIMP1
expression; however, this was not significant, while
the PI3K inhibitor appeared to enhance the expres-
sion of TIMP1 which reflects previous reports that
inhibition of PI3K correlated with induction of
TIMP1 [41, 42].
As mentioned previously, an initial priming signal is
required to drive pro-IL-1β expression prior to its subse-
quent proteolytic processing and release. The standard
in vitro system utilises LPS for priming cells; however,
this is unlikely to act as signal 1 in the context of OA
and it has been suggested that DAMPs released at the
site of injury can assume this role in vivo. Given that
S100A8 is capable of activating TLR4 and is shown here
to be induced by BCP crystals, we next examined if sub-
stitution of endotoxin-free recombinant S100A8 for LPS
was sufficient to facilitate pro-IL-1β induction prior to
BCP-induced processing in vitro. Primary human macro-
phages were primed with S100A8 for 3 h and then stim-
ulated with BCP crystals for 6 h, and cytokine
production was quantified. Both IL-1β and IL-1α were
found to be significantly elevated following S100A8
priming and BCP stimulation (Fig. 7), suggesting that
the DAMP can indeed induce pro-IL-1β expression. As
expected, given that S100A8 is a TLR4 ligand, TNFα was
also induced following S100A8 treatment (data not
shown). Taken together, these results suggest that, in
addition to pro-inflammatory cytokine production, Syk
and PI3K are involved in BCP crystal-induced S100A8,
S100A12, and MMP1 induction, making them attractive
therapeutic targets.
OA synovial fluid enhances BCP crystal-induced S100A8
and MMP1 production in a Syk-dependent manner
Having observed that OA-associated BCP crystals drive
S100A8, S100A12, and MMP1 expression in human in-
nate immune cells, we next sought to examine 1)
whether synovial fluid from OA patients exerts a similar
effect to the crystals, and 2) whether BCP crystals and
OA synovial fluid synergise to promote cartilage dam-
age. Primary human macrophages from healthy donors
were treated with synovial fluid from one of three OA
patients (A, B, or C) either alone or in the presence of
BCP crystals for 24 h, and expression of S100A8 and
Fig. 5 BCP crystals induce expression of damage-associated molecules and MMPs in primary human macrophages in a Syk- and PI3K-dependent
manner. Human macrophages (0.5 × 106 cells/well) were stimulated with BCP crystals (50 μg/ml) for 3, 6, and 24 h, and mRNA levels of a S100A8,
b S100A12, c MMP1, d MMP2, e MMP9, and f TIMP1 were analysed by real-time PCR. Alternatively, supernatants were harvested; whole cell lysates
(WCL) were prepared and both were analysed for the presence of g S100A8, h S100A12, and i MMP1 protein by immunoblotting. Representative
blots of three independent experiments are shown. *P≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001
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MMP1 was analysed by real-time PCR (Fig. 8a–c). As
previously observed, BCP crystals alone upregulated the
expression of both S100A8 and MMP1. Using a Stu-
dent’s paired t test to analyse the effect of OA synovial
fluid alone versus no treatment, expression of S100A8
was significantly increased as previously observed; P
values: A = 0.04, B = 0.06, C = 0.02. Interestingly, co-
treatment with OA synovial fluid and BCP crystals led
to higher levels of both S100A8 and MMP1 when com-
pared with either synovial fluid or BCP crystals alone.
Furthermore, pre-treatment of macrophages with the
Syk inhibitor R788 dampened the synergistic effects
observed following co-treatment, suggesting that R788 is
effective in the presence of synovial fluid, which is im-
portant when considering the optimum method of ad-
ministration of an OA drug.
Discussion
BCP crystals are associated with a number of rheumatic
syndromes, and particularly with OA where the HA
form of these crystals is most prevalent and is found to
be deposited in the joints of 70% of total OA cases and
in 100% of knee and hip osteoarthritic joints requiring
arthroplasty. The crystals can be found in the synovial
fluid and cartilage and are thought to form as a result of
dysregulated ossification processes. They are known to
play a pathogenic role in OA through the activation of
macrophages, synovial fibroblasts, and articular chon-
drocytes [3, 7, 22, 43–45]. This study provides further
insight into the mechanism by which BCP crystals acti-
vate intracellular signalling pathways in human innate
immune cells and induce pro-inflammatory cytokine
production. We report that BCP crystals activate the
Fig. 6 BCP crystals induce expression of S100A8, S100A12, and MMP1 in primary macrophages in a Syk-, PI3K-, and ERK-dependent manner.
Human macrophages were pre-treated with a piceatannol (50 μM, 100 μM), b LY294002 (25 μM, 50 μM), or c PD98059 (5 μM, 10 μM) for 30
mins prior to stimulation with BCP crystals for 24 h. mRNA levels of S100A8, S100A12, MMP1, and TIMP1 were analysed by real-time PCR.
Results indicate mean (± SEM) of three independent experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001
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membrane-proximal kinase Syk and its interacting part-
ner PI3K, and demonstrate that pharmacological inhib-
ition of these enzymes abrogates BCP-induced IL-1α
and IL-1β production. We demonstrate that, like gout-
associated MSU crystals, alum particles, and cholesterol
crystals, BCP crystals also activate Syk by MATS. In all
cases, disruption of lipid rafts with M-βCD prevents the
ITAM phosphorylation which normally ensues following
the direct binding of the particulates to the cell mem-
brane and thus prevents the recruitment and activation
of Syk [24–27]. Furthermore, this results in a significant
impairment of IL-1 production. Atomic Force Micros-
copy could be used for a more in-depth analysis to con-
firm that BCP crystals are, indeed, mediating their
effects on macrophages through a direct interaction with
the cell membrane. In addition to driving cell activation,
this interaction is likely to cause cell damage, leading to
the release of DAMPs which may propagate the initial
inflammatory response. Interestingly, phosphorylation of
the two subunits of PI3K appears to be regulated differ-
ently by BCP crystals, and further study is required to
determine if these events are mutually exclusive. We
have also shown that BCP crystals activate MEK and
ERK MAPK downstream of Syk and PI3K, thus provid-
ing a link between the initial immune cell activation and
subsequent gene expression. The PI3K pathway is a po-
tential target for OA treatment as it can regulate gene
expression through its target proteins which include NF-
κB, a transcription factor that is reported to regulate
MMP production [46, 47]. We demonstrate that BCP
Fig. 7 S100A8 primes human macrophages for BCP-induced IL-1β
production. Human macrophages were primed with recombinant
human S100A8 (1 μg/ml) for 3 h prior to stimulation with BCP for
6 h. Cell supernatants were assessed for IL-1β, IL-1α, and TNF-α by
ELISA. Results indicate mean (± SEM) of three independent
experiments. ***P ≤ 0.001
Fig. 8 BCP crystals exert synergistic effects with OA synovial fluid on primary macrophages. Human macrophages (0.5 × 106 cells/well) were
pre-treated with R788 (2.5 μM) prior to treatment with BCP crystals alone, synovial fluid from one of three OA patients (a, b or c), or OA synovial fluid
and BCP crystals together for 24 h. Expression of (upper panel) S100A8 and (lower panel) MMP1 were analysed by real-time PCR. Results indicate mean
(± SEM) of at least three healthy macrophage donors treated with synovial fluid from one OA patient. *P≤ 0.05, **P≤ 0.01
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crystals directly induce the upregulation of the calgranu-
lins S100A8 and S100A12 as well as the cartilage-
degrading protease MMP1 in a Syk- and PI3K-dependent
manner, and report that the presence of OA synovial fluid
exacerbates the effects of BCP crystals on macrophages.
S100A8 was first identified in the context of RA
where both the serum and synovial concentration of it
and its binding partner, S100A9, were found to be ele-
vated in patient samples [48]. Recent studies using the
collagenase-induced OA model subsequently revealed a
potential catabolic role for these proteins in OA-
associated inflammation, revealing that S100A8 was
abundant in the synovium of both early-stage and late-
stage OA patients [35]. Of particular interest was the
observation that serum levels of S100A8 were markedly
higher in patients showing progression of OA, rather
than those without progression, suggesting that these
proteins may also be useful markers of disease advance-
ment. Interestingly, analysis of cartilage from OA pa-
tients revealed that the protein is found only in areas of
proteoglycan loss, suggesting a correlation between the
presence of S100A8/A9 and MMP activity leading to
aggrecan degradation [49]. The same study demon-
strated that stimulation of cartilage explants with
S100A8 and S100A9, or a combination of the two, led
to increased mRNA levels of MMPs 1, 9, and 13, as well
as IL-6, IL-8, and monocyte chemotactic protein-1, while
it significantly downregulated the expression of aggrecan
and type II collagen. A role for S100A12 has also been im-
plicated in OA, where immunohistochemical analyses re-
vealed that S100A12 expression was markedly increased
in OA cartilage compared to non-OA cartilage. The same
study also demonstrated that mRNA expression of
S100A12 was significantly upregulated in OA chondro-
cytes in vitro by IL-1β stimulation and that treatment of
OA chondrocytes with recombinant human S100A12 re-
sulted in a significant increase in MMP13 mRNA expres-
sion [38]. This suggests that S100 proteins may amplify
the inflammatory response and induce the degradation of
cartilage, while also preventing its repair and regeneration.
TLR4 has been identified as the key receptor for S100A8/
9 activity, and we have demonstrated that S100A8 can act
as a priming signal for BCP crystal-induced IL-1β matur-
ation (at least in an in vitro context). Hence, small mol-
ecule inhibitors or biologics targeting TLR4 and/or
relevant S100 proteins may be of benefit to OA patients.
Furthermore, Syk and PI3K appear to be activated up-
stream of gene transcription as pharmacological inhibition
of these molecules reduces BCP crystal-induced S100A8
and MMP1 mRNA. Therefore, Syk and PI3K may also
represent potential therapeutic targets. Indeed, preventing
the actual deposition of calcium crystals, as recently dem-
onstrated in a murine OA model by Nasi et al. [50], could
limit these responses in the first instance and prevent
crystal-associated cell inflammation. Expression of Syk
and PI3K has been detected in the intimal lining of OA
synovial tissues at similar levels to those detected in
healthy synovial tissue, though the degree of activation
compared to healthy synovial tissue has not been investi-
gated in any detail [51, 52]. Furthermore, Syk is also
known to be expressed by osteoclasts and is crucial to
osteoclastic bone resorption [53]; therefore, further studies
are required to determine if Syk activation is heightened
in OA joints.
Conclusions
The studies presented here demonstrate that BCP
crystals are capable of activating specific intracellular
signalling pathways which drive inflammation and the
production of cartilage-degrading enzymes and DAMPs
that promote disease initiation and exacerbate progression
in OA. Patients are currently treated with intra-articular
corticosteroids and non-steroidal anti-inflammatory drugs
to provide symptomatic relief. Corticosteroids have previ-
ously been demonstrated to reduce early OA changes such
as osteophyte formation and cartilage lesion in a canine
OA model [54] and to reduce cartilage degradation when
administered early after anterior cruciate ligament injury
in a porcine model [55]; however, they do not entirely halt
disease progression. Clinical trials are currently underway
to examine the effect of intra-articular administration of a
synthetic glucocorticoid on pain, joint function, inflamma-
tion, and cartilage degradation (ClinicalTrials.gov identi-
fier: NCT01692756). Anti-cytokine, anti-MMP therapies,
and anti-S100A8/A9 therapies are promising candidates
for new disease-modifying OA drugs. However, preventing
the expression and/or release of degradative mediators ra-
ther than inhibiting their activity may prove more effi-
cient. Membrane-proximal kinases such as Syk and PI3K
require consideration not just in the context of OA but
also for other crystal-mediated diseases such as gout and
atherosclerosis, and in vivo studies are required in order
to fully implicate these kinases in crystal-induced re-
sponses. The orally available Syk inhibitor R788 that was
used in this study has previously shown efficacy in clinical
trials for rheumatoid arthritis; however, reports of side ef-
fects during phase III trials led to trial termination [56].
Nevertheless, a modification on the current drug or, in-
deed, an alternate method of administration, such as
direct injection into the joint, may still prove to be ef-
fective as a treatment for OA. Indeed, Syk inhibitors
are currently in development by a number of pharma-
ceutical companies.
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